Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: MediGene
Woman and Man Max 99 years
MediGene AG
Update Il y a 4 ans
An open-label, uncontrolled, Phase II trial evaluating the single-dose and steady-state pharmacokinetics of EndoTAG®-1 and its effect on the blood supply and the angiogenesis of hepatic metastases in patients with a carcinomatous primary tumor other than hepatocellular (HCC), biliary or bile duct carcinoma
To assess the pharmacokinetic profile of EndoTAG-1 (22mg/m²) after single-dose and in steady-state
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
MediGene AG
Update Il y a 4 ans
An open-label, randomized, controlled Phase-II trial evaluating the efficacy and safety of EndoTAG-1 in triple receptor negative breast cancer patients
Primary objective is to assess the efficacy of EndoTAG-1 + paclitaxel (combination therapy) and EndoTAG-1 (monotherapy) as a rescue therapy for patients with triple receptor negative relapsed or metas...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
MediGene AG
Update Il y a 4 ans
A Controlled, Randomized, Open label Phase II Trial to Evaluate Safety and Efficacy of a 1st line Combination Treatment with Weekly Infusion of Gemcitabine and Twice Weekly Administration of Lipid Complexed Paclitaxel (EndoTAG®-1) in Three Dose Levels Compared with Gemcitabine Monotherapy in Patients with Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas
Safety Objectives: - Assessment of the safety of biweekly infusions of EndoTAG™-1 and weekly infusions of gemcitabine via: - Incidence and percentage with patients EndoTAG™-1 and gemcitabine relat...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman
Between 18 years
and 99 years
MediGene
Update Il y a 4 ans
MediGene CT 4002 : Essai de phase 2 randomisé évaluant l’efficacité et la tolérance de l’association endoTAG-1, paclitaxel chez des patientes ayant un cancer du sein. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
An open-label, randomized, controlled phase-II trial evaluating the efficacy and safety of endoTAG-1 in triple receptor negative breast cancer patients.
Country
France
organs
Sein
Specialty
Thérapies Ciblées
,
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
MediGene AG (Germany)
Update Il y a 4 ans
EndoTAG®-1 and Gemcitabine Combination Therapy for the Treatment of Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas
Not provided at time of registration
Country
None
organs
None
Specialty
None
Closed trial
More information